Highlights
- Market Cap
- $168.61M
- Enterprise Value
- $136.98M
- EPS (TTM)
- -$1.31
- Year Range
- $5.55 - $11.52
- Target Price
- $10.00
- ROA (TTM)
- -91.05%
- ROE (TTM)
- -156.80%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Nuvectis Pharma Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Nuvectis Pharma Inc (NVCT) has returned 2.38% so far this year and -20.88% over the past 12 months.
Nuvectis Pharma Inc
- 1D
- 3.20%
- 1M
- -12.75%
- YTD
- 2.38%
- 6M
- 28.41%
- 1Y
- -20.88%
- 3Y*
- -16.15%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Feb 4, 2022, NVCT's average daily return is +0.28%, while the average monthly return is +4.09%. At this rate, your investment would double in approximately 1.4 years.
Historically, 50% of months were positive and 50% were negative. The best month was Feb 2022 with a return of +111.4%, while the worst month was Nov 2024 at -32.5%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 5 months.
On a daily basis, NVCT closed higher 49% of trading days. The best single day was Feb 7, 2022 with a return of +144.6%, while the worst single day was Nov 14, 2024 at -46.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.42% | 9.25% | -12.75% | 2.38% | |||||||||
| 2025 | 24.95% | -1.04% | 46.04% | 1.94% | -5.52% | -20.62% | -6.83% | -5.75% | -8.23% | 11.46% | -7.00% | 20.99% | 39.56% |
| 2024 | -12.59% | 35.39% | -16.92% | -25.85% | 11.35% | -6.50% | 0.32% | 9.61% | -9.63% | 18.76% | -32.53% | 7.34% | -35.13% |
| 2023 | 32.27% | 15.22% | 14.70% | 12.89% | 18.24% | -8.74% | -12.02% | 1.85% | -9.92% | -30.57% | -5.03% | -1.88% | 11.20% |
| 2022 | 111.38% | 7.86% | 28.21% | 58.21% | -25.48% | -21.43% | -7.95% | -12.47% | -4.37% | 8.41% | 2.04% | 130.77% |
Benchmark Metrics
Nuvectis Pharma Inc has an annualized alpha of 94.82%, beta of 0.42, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since February 07, 2022.
- This stock captured 14.45% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -140.36%) — a profile typical of hedging or uncorrelated assets.
- Beta of 0.42 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 94.82%
- Beta
- 0.42
- R²
- 0.00
- Upside Capture
- 14.45%
- Downside Capture
- -140.36%
Return for Risk
Risk / Return Rank
NVCT ranks 25 for risk / return — below 25% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Nuvectis Pharma Inc (NVCT) and compare them to a chosen benchmark (S&P 500 Index).
| NVCT | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.34 | 0.90 | -1.24 |
Sortino ratioReturn per unit of downside risk | -0.13 | 1.39 | -1.51 |
Omega ratioGain probability vs. loss probability | 0.99 | 1.21 | -0.22 |
Calmar ratioReturn relative to maximum drawdown | -0.54 | 1.40 | -1.94 |
Martin ratioReturn relative to average drawdown | -0.83 | 6.61 | -7.44 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore NVCT risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Nuvectis Pharma Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Nuvectis Pharma Inc was 77.89%, occurring on Dec 20, 2024. The portfolio has not yet recovered.
The current Nuvectis Pharma Inc drawdown is 62.18%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -77.89% | May 18, 2022 | 653 | Dec 20, 2024 | — | — | — |
| -33.74% | Mar 15, 2022 | 5 | Mar 21, 2022 | 12 | Apr 6, 2022 | 17 |
| -31.95% | Feb 8, 2022 | 5 | Feb 14, 2022 | 15 | Mar 8, 2022 | 20 |
| -21.87% | May 9, 2022 | 2 | May 10, 2022 | 3 | May 13, 2022 | 5 |
| -11.8% | Apr 7, 2022 | 15 | Apr 28, 2022 | 3 | May 3, 2022 | 18 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Nuvectis Pharma Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Nuvectis Pharma Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NVCT in comparison with other companies in the Biotechnology industry. Currently, NVCT has a P/B value of 9.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |